View:
Download DOC
Download PDF
Download XLS
Download XBRL
8-K
false000165653600016565362022-06-172022-06-17

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 17, 2022

 

 

Decibel Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40030

46-4198709

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1325 Boylston Street

Suite 500

 

Boston, Massachusetts

 

02215

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (617) 370-8701

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, $0.001 par value per share

 

DBTX

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 


 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

Decibel Therapeutics, Inc. (the “Company”) held its 2022 annual meeting of stockholders on June 17, 2022. The following is a summary of the matters voted on at that meeting.

 

(a)
The stockholders of the Company elected one Class I director, Alison Finger, M.B.A., to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until her successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of the Class I director were as follows:

 

Name

 

For

 

Withheld

 

Broker Non-Votes

Alison Finger, M.B.A.

 

17,996,169

 

25,861

 

3,123,761

 

(b)
The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 21,129,235

 

2,824

 

13,732

 

—


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

DECIBEL THERAPEUTICS, INC.

 

 

 

 

Date:

June 17, 2022

By:

/s/ Elisabeth Leiderman

 

 

 

Name: Elisabeth Leiderman, M.D.
Title: Chief Financial Officer and Head of Corporate Development